Elanco Animal Health (NYSE:ELAN) Releases FY 2025 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 0.910-0.940 for the period, compared to the consensus estimate of 0.900. The company issued revenue guidance of $4.6 billion-$4.7 billion, compared to the consensus revenue estimate of $4.6 billion. Elanco Animal Health also updated its Q4 2025 guidance to 0.090-0.120 EPS.

Elanco Animal Health Stock Down 0.8%

Shares of ELAN traded down $0.18 on Thursday, hitting $21.43. 3,099,197 shares of the stock traded hands, compared to its average volume of 5,912,403. The company has a market capitalization of $10.64 billion, a PE ratio of 24.90, a P/E/G ratio of 3.51 and a beta of 1.71. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. The business has a 50 day simple moving average of $20.05 and a 200 day simple moving average of $16.03. Elanco Animal Health has a one year low of $8.02 and a one year high of $22.98.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter last year, the company posted $0.13 earnings per share. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. As a group, equities analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on ELAN. Zacks Research raised shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 3rd. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday. UBS Group boosted their price objective on shares of Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday. Stifel Nicolaus boosted their price objective on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Finally, Leerink Partners raised shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price objective for the company in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.29.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ELAN. Geneos Wealth Management Inc. increased its stake in shares of Elanco Animal Health by 53.7% in the second quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company’s stock worth $85,000 after acquiring an additional 2,080 shares during the period. EverSource Wealth Advisors LLC grew its position in shares of Elanco Animal Health by 26.4% in the second quarter. EverSource Wealth Advisors LLC now owns 6,379 shares of the company’s stock valued at $91,000 after purchasing an additional 1,332 shares during the period. Cresset Asset Management LLC grew its position in shares of Elanco Animal Health by 12.8% in the second quarter. Cresset Asset Management LLC now owns 11,338 shares of the company’s stock valued at $162,000 after purchasing an additional 1,287 shares during the period. Empowered Funds LLC lifted its stake in shares of Elanco Animal Health by 35.2% in the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after buying an additional 4,121 shares in the last quarter. Finally, Vident Advisory LLC lifted its stake in shares of Elanco Animal Health by 14.5% in the second quarter. Vident Advisory LLC now owns 16,952 shares of the company’s stock worth $242,000 after buying an additional 2,144 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.